Physician profile
Jae Kim
NPI 1083685218
$1,350.14
in general payments reported to CMS, 2019-2025
14 companies · $414 in 2025
The $414 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.46 · 2020: $38.18 · 2021: $99.05 · 2022: $267 · 2023: $165 · 2024: $320 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $898.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $899.74 | 2019-2025 | |
| Gilead Sciences, INC. | $121.84 | 2025 | Livdelzi |
| Janssen Biotech, INC. | $71.78 | 2024-2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $53.70 | 2019-2020 | |
| Teleflex LLC | $40.71 | 2022 | |
| Olympus America INC. | $39.13 | 2019-2024 | Endoclot Sis |
| Braintree Laboratories, INC. | $23.84 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.34 | 2024 | Voquezna |
| Novo Nordisk INC | $15.74 | 2025 | Wegovy |
| Ardelyx, INC. | $15.67 | 2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.88 | 2023 | Xifaxan |
| Celgene Corporation | $13.76 | 2024 | Zeposia |
| Conmed Corporation | $11.93 | 2022 | |
| Elutia, INC. | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jae Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.